CooperCompanies (COO) Q1 2026 earnings review
Profitability Surges on Synergies as Revenue Growth Stabilizes
CooperCompanies delivered a robust start to fiscal 2026, driven by exceptional profitability rather than top-line acceleration. While total organic revenue grew a stable 3%, Non-GAAP operating margin expanded a massive 180 basis points to 27%, fueled by recent reorganization synergies. This operational leverage successfully absorbed a 60 bps gross margin hit from tariffs and drove a 20% YoY increase in Non-GAAP EPS. Management confidently raised FY26 EPS and free cash flow guidance, leaning heavily into their $2.2 billion multi-year FCF target and ongoing share repurchases.
🐂 Bull Case
The fiscal 2025 reorganization is paying off immediately. Despite gross margin headwinds, disciplined execution drove Non-GAAP operating margin to 27%, proving management's ability to extract operating expense leverage.
Q1 Free Cash Flow surged 57% YoY to $158.7M. The company is firmly on track for its 2026-2028 target of $2.2B+ in FCF, providing immense flexibility for debt reduction and continued aggressive share buybacks ($92.5M in Q1 alone).
🐻 Bear Case
The CVI Asia Pacific segment is decelerating further, posting a 4% organic decline in Q1. Continued weakness in this region threatens to cap the ceiling on CooperVision's global growth.
Tariffs directly erased 60 basis points of gross margin in Q1. If the company cannot pass these costs along through pricing, gross margins will remain structurally lower, forcing SG&A to do all the heavy lifting for earnings growth.
⚖️ Verdict: 🟢
Bullish. The top-line growth is unexciting at 3%, but the quality of earnings is superb. The company has proven it can overcome tariff-driven gross margin compression through structurally improved operating efficiency, paving the way for superior EPS and cash flow generation.
Key Themes
Operating Leverage and Synergy Realization
Accelerating. Non-GAAP Operating Margin increased 180 basis points YoY to 27%, despite flat to negative gross margin momentum. This is a direct result of the $89 million reorganization completed in Q4 2025, which aimed for $50 million in annual savings. The IT implementations and back-office optimizations are now visibly flowing to the bottom line.
Asia Pacific Contraction
Decelerating. CooperVision's Asia Pacific segment posted a 4% organic revenue decline in Q1 (down to $123.8M). This region has been a persistent sore spot since early FY25 (down 5% in Q3 25, down 1% in Q4 25), primarily plagued by low-margin e-commerce weakness in China. This specific data point directly contradicts the optimistic narrative of a globally robust contact lens market.
Macro Impact: Tariff Gross Margin Headwinds
Stable but negative. Non-GAAP gross margin was down 60 basis points YoY to 68%. Management explicitly noted that excluding the impact of tariffs, gross margin would have been flat year-over-year. While current operating efficiencies offset this, unmitigated supply chain costs remain a primary structural risk to profitability.
Premium Portfolio and Myopia Management Innovation
Accelerating. The Toric and multifocal segment grew 6% organically, easily outpacing the legacy Sphere category. The global rollout of the MyDay premium daily lens portfolio continues to gain traction, and management highlighted early momentum from the new MyDay MiSight launch, which bridges their premium lens material with their leading myopia management technology.
Sphere and Legacy Lenses Stalling
Decelerating. CVI's Sphere/Other category grew a sluggish 1% organically to $343.9M in Q1. This compares to 3% growth in both 25Q1 and 25Q4. As the company aggressively pushes practitioners to trade patients up to the premium MyDay portfolio, the legacy Clarity and Sphere volume is naturally cannibalized, dragging down blended growth rates.
Aggressive Capital Returns
Stable. The company repurchased 1.1 million shares for $92.5 million in Q1 at an average price of $82.04. This marks an acceleration from previous quarters (e.g., $40.6M in 25Q2, $52.1M in 25Q3) and shows management is fully utilizing the expanded $2 billion authorization to drive EPS.
Other KPIs
Accelerating. FCF jumped 57% from $101.2 million in 25Q1, driven by a combination of higher net income, favorable working capital dynamics, and capital expenditures beginning to normalize ($102.2M in Q1). This provides the essential fuel for their aggressive buyback program.
Decelerating. Down from $26.0 million in 25Q1, driven by lower average debt levels. This consistent deleveraging frees up more cash flow to be funneled directly to equity holders rather than creditors.
Guidance
Accelerating. The midpoint implies full-year organic growth of 4.5% to 5.5%. Because Q1 organic growth was only 3%, achieving this full-year guidance requires a significant acceleration in the remaining three quarters of FY26.
Accelerating. Raised from previous internal expectations. The midpoint of $4.62 represents an 11.8% YoY growth over FY25's $4.13. This strong bottom-line guidance, contrasted with single-digit revenue growth, underscores the heavy reliance on margin expansion and share repurchases.
Accelerating. Raised outlook and firmly above the $433.7 million generated in FY25. This sets the foundation for the company's multi-year target of $2.2 billion in FCF from 2026 through 2028.
Accelerating. Organic growth guided to 4.5% to 5.5%. Q1 organic growth was just 3%, meaning the company is heavily relying on a ramp-up in new MyDay private label contracts and product launches in Q2-Q4 to hit these targets.
Key Questions
Asia Pacific Recovery Timeline
The APAC region contracted 4% organically this quarter, extending a multi-quarter trend of underperformance. What specific structural changes or product launches are required to return this region to growth, and is that modeled into the back-half FY26 acceleration?
Tariff Mitigation Strategy
Tariffs eroded 60 bps of gross margin in Q1. Beyond the SG&A leverage that offset this, what specific supply chain realignments or pricing actions are currently underway to claw back that gross margin structurally?
MyDay MiSight Adoption
You noted early traction with MyDay MiSight. How does the pricing and margin profile of this combination lens compare to the standard MiSight, and what is the target conversion rate from legacy platforms?
Organic Acceleration Visibility
Full-year guidance requires 4.5%-5.5% organic growth, yet Q1 delivered only 3%. How much of the required acceleration in Q2-Q4 is dependent on already-signed private label contracts versus assumed market share gains that have yet to materialize?